Kolon Life Science Balance Sheet Health
Financial Health criteria checks 3/6
Kolon Life Science has a total shareholder equity of ₩159.7B and total debt of ₩122.7B, which brings its debt-to-equity ratio to 76.9%. Its total assets and total liabilities are ₩350.7B and ₩191.0B respectively.
Key information
76.9%
Debt to equity ratio
₩122.74b
Debt
Interest coverage ratio | n/a |
Cash | ₩8.39b |
Equity | ₩159.69b |
Total liabilities | ₩191.01b |
Total assets | ₩350.70b |
Recent financial health updates
We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt
Mar 12Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt
Nov 26Recent updates
Risks Still Elevated At These Prices As Kolon Life Science Inc. (KOSDAQ:102940) Shares Dive 26%
Mar 02We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt
Mar 12A Look At Kolon Life Science's (KOSDAQ:102940) Share Price Returns
Jan 18Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt
Nov 26Financial Position Analysis
Short Term Liabilities: A102940's short term assets (₩113.6B) do not cover its short term liabilities (₩141.1B).
Long Term Liabilities: A102940's short term assets (₩113.6B) exceed its long term liabilities (₩50.0B).
Debt to Equity History and Analysis
Debt Level: A102940's net debt to equity ratio (71.6%) is considered high.
Reducing Debt: A102940's debt to equity ratio has increased from 74.1% to 76.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A102940 has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: A102940 is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.